The INTERCEPT Cryoprecipitate system is a pathogen inactivation technology designed to reduce the risk of infectious agents in cryoprecipitate transfusions. It provides pathogen inactivation for fibrinogen-containing blood products.
Manufactured by
Cerus Europe B.V.
Netherlands
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and transfusion services worldwide.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 6 closest product alternatives
Nanjing Shuangwei Biotechnology Co., Ltd · China
Medical equipment designed to inactivate viruses in plasma as part of the blood safety and transfusion process. This device provides pathogen inactivation functionality to enhance the safety of blood products used in clinical settings.
SHANDONG ZHONGBAOKANG MEDICAL IMPLEMENTS CO LTD · China
Advanced filtration technology for plasma products to inactivate or remove viral contaminants. Enhances transfusion safety by reducing risk of virus transmission through plasma administration.
Nanjing Shuangwei Biotechnology Co., Ltd · China
A transfusion device designed for viral inactivation purposes during blood product processing and transfusion procedures.
3 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products